Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

UK MHRA Aims To Cast Early Access Scheme In New Light

Agency Wants To Make EAMS More Attractive To Sponsors Of Innovative Medicines

Executive Summary

The UK’s Early Access to Medicines Scheme continues to provide important flexibility, but companies also now have the option of a new ambitious pathway launched this year for accelerating time to market for innovative medicines.

You may also be interested in...



New UK Drug Applications At ‘Sustained Levels’ Post-Brexit

The MHRA’s chief executive explains to the Pink Sheet how the agency will ensure the UK remains an attractive place to seek approval of new innovative drugs and build on the regulatory flexibilities introduced during the COVID-19 pandemic.

UK’s Early Access To Medicines Scheme To Get New Legal Basis

Legal clarity around the core principles of the UK’s early patient access scheme is expected to benefit the pharma industry, patients and healthcare professionals.

UK Wants Early Access Scheme To Remain ‘Relevant And Attractive’ Following Brexit

The MHRA has drawn up measures to improve regulatory certainty around the UK’s early patient access scheme while reducing regulatory burden in certain areas of its operation.

Related Content

Topics

UsernamePublicRestriction

Register

PS144749

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel